3SBio Inc. is a prominent biotechnology company primarily engaged in the research, development, manufacturing, and commercialization of biopharmaceutical products. Its core focus lies in developing innovative treatment options for patients suffering from cancer, nephrology, and autoimmune diseases. Notably, the company produces erythropoietin, a hormone crucial for red blood cell production, which positions it as a key player in the treatment of anemia caused by chronic kidney disease and chemotherapy. 3SBio also explores cutting-edge therapies, including monoclonal antibodies and other biologics, highlighting its commitment to advancing healthcare solutions. This company plays an integral role in the biotechnology sector by contributing to the availability of affordable and effective medicines, especially within the Chinese healthcare system where it is based. Its strategic operations, extensive portfolio, and research initiatives ensure its significance in addressing unmet medical needs and enhancing patient quality of life. Founded in 1993, 3SBio continues to expand its influence in Asia and globally by collaborating with international partners and leveraging advancements in biotechnological research and development.